Agios Pharmaceuticals Inc (STU:8AP)
€ 42 0.2 (0.51%) Market Cap: 2.40 Bil Enterprise Value: 1.90 Bil PE Ratio: 0 PB Ratio: 3.45 GF Score: 41/100

Agios Pharmaceuticals Inc Virtual Investor Event to Review Data Presented at ASH Transcript

Dec 08, 2020 / 01:00PM GMT
Release Date Price: €33.84 (-8.89%)
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Good morning, everyone. Thank you for joining us this morning for our Agios ASH 2020 virtual investor event. I'm Jackie Fouse, the CEO and we have several members of the team with us today, who you will hear from and see in just a moment.

Let me start by flashing our forward-looking statements across the screen. There you have those.

Today, here's the agenda that we have. I have some quick opening remarks to get us started. I'll then turn it over to Chris Bowden, our Chief Medical Officer, who will talk about mitapivat, our PKR activator; AG-348 and its mechanism of action; and give you some clinical updates, including about our thalassemia pivotal trial plan. And he'll also cover the top line ACTIVATE data that we released last week. And then we'll spend the bulk of the discussion this morning with Dr. Swee Lay Thein, who will go through her slides on sickle cell disease, and we'll move into a Q&A. So thank you again for joining us.

Patients have been at the core of everything that we do at Agios since

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot